Imprida

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

valsartan, amlodipine (as amlodipine besilate)

Available from:

Novartis Europharm Ltd

ATC code:

C09DB01

INN (International Name):

amlodipine, valsartan

Therapeutic group:

Sredstva, ki delujejo na sistem renin-angiotenzin

Therapeutic area:

Hipertenzija

Therapeutic indications:

Zdravljenje esencialne hipertenzije. Imprida je indicirana pri bolnikih, katerih krvni tlak ni ustrezno nadzorovan na amlodipine ali valsartan monotherapy.

Product summary:

Revision: 20

Authorization status:

Umaknjeno

Authorization date:

2007-01-17

Patient Information leaflet

                                66
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Shranjujte pri temperaturi do 30 °C.
Shranjujte v originalni ovojnini za zagotovitev zaščite pred vlago.
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Novartis Europharm Limited
Frimley Business Park
Camberley GU16 7SR
Velika Britanija
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/06/373/001
7 filmsko obloženih tablet
EU/1/06/373/002
14 filmsko obloženih tablet
EU/1/06/373/003
28 filmsko obloženih tablet
EU/1/06/373/004
30 filmsko obloženih tablet
EU/1/06/373/005
56 filmsko obloženih tablet
EU/1/06/373/006
90 filmsko obloženih tablet
EU/1/06/373/007
98 filmsko obloženih tablet
EU/1/06/373/008
280 filmsko obloženih tablet
EU/1/06/373/025
56x1 filmsko obložena tableta (za enkratni odmerek)
EU/1/06/373/026
98x1 filmsko obložena tableta (za enkratni odmerek)
EU/1/06/373/027
280x1 filmsko obložena tableta (za enkratni odmerek)
13.
ŠTEVILKA SERIJE
Serija
14.
NAČIN IZDAJANJA ZDRAVILA
Predpisovanje in izdaja zdravila je le na recept.
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Imprida 5 mg/80 mg
Zdravilo nima več dovoljenja za promet
67
PODATKI NA ZUNANJI OVOJNINI
VMESNA ŠKATLA SKUPNEGA PAKIRANJA (BREZ “BLUE BOX” PODATKOV)
1.
IME ZDRAVILA
Imprida 5 mg/80 mg filmsko obložene tablete
amlodipin/valsartan
2.
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN
Ena tableta vsebuje 5 mg amlodipina (v obliki amlodipinijevega
besilata) in 80 mg valsartana.
3.
SEZNAM POMOŽNIH SNOVI
4.
FARMACEVTSKA OBLIKA IN VSEBINA
70 filmsko obloženih tablet (del skupnega pakiranja, ni namenjen
ločeni prodaji).
14 filmsko obloženih tablet (del skupnega pakiranja, ni namenjen
ločeni prodaji).
5.
POSTOPEK IN POT(I) UPORABE ZDRAVILA
_ _
Pred uporabo preberite priloženo navodilo!
Peroralna uporaba.
6.
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN
POGLEDA OTROK
Zdravilo shranjujte nedosegljivo otrokom!
7.
DRUGA POSEBNA OPOZOR
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
Zdravilo nima več dovoljenja za promet
2
1.
IME ZDRAVILA
Imprida 5 mg/80 mg filmsko obložene tablete
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Ena filmsko obložena tableta vsebuje 5 mg amlodipina (v obliki
amlodipinijevega besilata) in 80 mg
valsartana.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
Filmsko obložena tableta.
Temnorumene, okrogle filmsko obložene tablete s poševnimi robovi, ki
imajo na eni strani oznako
“NVR” in na drugi “NV”.
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Zdravljenje esencialne hipertenzije.
Zdravilo Imprida je indicirano pri odraslih, pri katerih krvni tlak ni
ustrezno urejen ob monoterapiji z
amlodipinom ali valsartanom.
4.2
ODMERJANJE IN NAČIN UPORABE
Odmerjanje
Priporočeni odmerek zdravila Imprida je ena tableta na dan.
Zdravilo Imprida 5 mg/80 mg lahko uporabite pri bolnikih, pri katerih
krvni tlak ni ustrezno urejen
samo s 5 mg amlodipina ali z 80 mg valsartana.
Bolnik lahko zdravilo Imprida vzame s hrano ali brez nje.
Pred prehodom na kombinacijo s fiksnim odmerkom je priporočljivo
individualno titriranje odmerka
sestavin (tj. amlodipina in valsartana). Če je klinično primerno, je
možno na kombinacijo s fiksnim
odmerkom preiti neposredno z monoterapije.
Zaradi praktičnosti je možno bolnike, ki dobivajo valsartan in
amlodipin v ločenih tabletah/kapsulah,
prevesti na zdravilo Imprida, ki vsebuje enaka odmerka sestavin.
_ _
_Okvara ledvic _
O uporabi zdravila pri bolnikih s hudo okvaro ledvic ni na voljo
nobenih kliničnih podatkov.
ImpridaBolnikom z blago do zmerno okvaro ledvic odmerka ni treba
prilagoditi. Pri bolnikih z zmerno
okvaro ledvic je priporočljivo kontrolirati koncentracije kalija in
kreatinina.
_Okvara jeter _
Pri bolnikih s hudo okvaro jeter je zdravilo Imprida kontraindicirano
(glejte poglavje 4.3).
Zdravilo nima več dovoljenja za promet
3
Previdnost je potrebna pri uporabi zdravila Imprida pri bolnikih z
okvaro jeter ali obstruktivno
biliarno boleznijo (gle
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 11-05-2017
Summary of Product characteristics Summary of Product characteristics Bulgarian 11-05-2017
Public Assessment Report Public Assessment Report Bulgarian 11-05-2017
Patient Information leaflet Patient Information leaflet Spanish 11-05-2017
Public Assessment Report Public Assessment Report Spanish 11-05-2017
Patient Information leaflet Patient Information leaflet Czech 11-05-2017
Public Assessment Report Public Assessment Report Czech 11-05-2017
Patient Information leaflet Patient Information leaflet Danish 11-05-2017
Public Assessment Report Public Assessment Report Danish 11-05-2017
Patient Information leaflet Patient Information leaflet German 11-05-2017
Public Assessment Report Public Assessment Report German 11-05-2017
Patient Information leaflet Patient Information leaflet Estonian 11-05-2017
Public Assessment Report Public Assessment Report Estonian 11-05-2017
Patient Information leaflet Patient Information leaflet Greek 11-05-2017
Public Assessment Report Public Assessment Report Greek 11-05-2017
Patient Information leaflet Patient Information leaflet English 11-05-2017
Public Assessment Report Public Assessment Report English 11-05-2017
Patient Information leaflet Patient Information leaflet French 11-05-2017
Public Assessment Report Public Assessment Report French 11-05-2017
Patient Information leaflet Patient Information leaflet Italian 11-05-2017
Public Assessment Report Public Assessment Report Italian 11-05-2017
Patient Information leaflet Patient Information leaflet Latvian 11-05-2017
Public Assessment Report Public Assessment Report Latvian 11-05-2017
Patient Information leaflet Patient Information leaflet Lithuanian 11-05-2017
Summary of Product characteristics Summary of Product characteristics Lithuanian 11-05-2017
Public Assessment Report Public Assessment Report Lithuanian 11-05-2017
Patient Information leaflet Patient Information leaflet Hungarian 11-05-2017
Summary of Product characteristics Summary of Product characteristics Hungarian 11-05-2017
Public Assessment Report Public Assessment Report Hungarian 11-05-2017
Patient Information leaflet Patient Information leaflet Maltese 11-05-2017
Public Assessment Report Public Assessment Report Maltese 11-05-2017
Patient Information leaflet Patient Information leaflet Dutch 11-05-2017
Public Assessment Report Public Assessment Report Dutch 11-05-2017
Patient Information leaflet Patient Information leaflet Polish 11-05-2017
Public Assessment Report Public Assessment Report Polish 11-05-2017
Patient Information leaflet Patient Information leaflet Portuguese 11-05-2017
Summary of Product characteristics Summary of Product characteristics Portuguese 11-05-2017
Public Assessment Report Public Assessment Report Portuguese 11-05-2017
Patient Information leaflet Patient Information leaflet Romanian 11-05-2017
Public Assessment Report Public Assessment Report Romanian 11-05-2017
Patient Information leaflet Patient Information leaflet Slovak 11-05-2017
Public Assessment Report Public Assessment Report Slovak 11-05-2017
Patient Information leaflet Patient Information leaflet Finnish 11-05-2017
Public Assessment Report Public Assessment Report Finnish 11-05-2017
Patient Information leaflet Patient Information leaflet Swedish 11-05-2017
Public Assessment Report Public Assessment Report Swedish 11-05-2017
Patient Information leaflet Patient Information leaflet Norwegian 11-05-2017
Summary of Product characteristics Summary of Product characteristics Norwegian 11-05-2017
Patient Information leaflet Patient Information leaflet Icelandic 11-05-2017
Summary of Product characteristics Summary of Product characteristics Icelandic 11-05-2017
Patient Information leaflet Patient Information leaflet Croatian 11-05-2017
Public Assessment Report Public Assessment Report Croatian 11-05-2017

Search alerts related to this product

View documents history